TITLE

Delivery of Factor VIII Gene into Skeletal Muscle Cells Using Lentiviral Vector

AUTHOR(S)
Hyun Jeong Jeon; Tae Keun Oh; Oak Hee Kim; Seung Taik Kim
PUB. DATE
January 2010
SOURCE
Yonsei Medical Journal;1/1/2010, Vol. 51 Issue 1, p52
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose: This study was designed to investigate whether transduction of lentiviral vectors (LV) carrying human coagulation factor VIII (hFVIII) cDNA into skeletal muscle could increase circulating hFVIII concentrations. Materials and Methods: A LV containing bacterial LacZ gene as a control or human FVIII gene was intra-muscularly administered into the thigh muscle of 5 weeks old Sparague-Dawley rats. The plasma human FVIII concentration and neutralizing anti-FVIII antibodies were measured for up to 12 weeks in these experimental animals. Results: The plasma human FVIII levels in the rats injected with LV carrying FVIII cDNA peaked at post-injection 1st week (5.19 ± 0.14 ng/mL vs. 0.21 + 0.05 ng/mL in control rats , p < 0.05). Elevated hFVIII concentrations were maintained for 4 weeks (2.52 ± 0.83 ng/mL vs. 0.17 ± 0.08 ng/mL in control rats, p < 0.05) after a single intramuscular injection. In the Bethesda assay, neutralizing antibodies for FVIII protein were detected only in FVIII-LV injected rats by the 10th week, but not in control rats. Conclusion: This study suggested that a single administration of an advanced generation LV carrying the human FVIII cDNA resulted in elevation of FVIII level in immune competent rats, and that this gene transfer approach to the skeletal muscle could be an effective tool in treatment of hemophilia A.
ACCESSION #
48169138

 

Related Articles

  • The Prevalence of Proteolytic Antibodies against Factor VIII in Hemophilia A. Lacroix-Desmazes, Sébastien; Bayry, Jagadeesh; Misra, Namita; Horn, Michael P.; Villard, Sylvie; Pashov, Anastas; Stieltjes, Natalie; d'Oiron, Roseline; Saint-Remy, Jean-Marie; Hoebeke, Johan; Kazatchkine, Michel D.; Reinbolt, Joseph; Mohanty, Dipika; Kaveri, Srini V. // New England Journal of Medicine;2/28/2002, Vol. 346 Issue 9, p662 

    Background: Factor VIII inhibitors are IgG alloantibodies that arise during replacement therapy in 25 to 50 percent of patients with severe hemophilia A. The hydrolysis of factor VIII by anti–factor VIII antibodies has been proposed as a mechanism of inactivation of factor VIII. Methods:...

  • Hybrid clotting factor means fewer injections, better disease control for hemophilia patients.  // eHEALTH;12/1/2013, p1 

    The article offers a report by researchers of the University of California in Davis, California on coagulation factor (rFIXFc) which reduces injections for clotting for hemophilia B patients. topics discussed include metabolizing the hybrid protein with clotting factor IX with an immunoglobulin...

  • Novel Hypolipidemic Agents: Focus on PCSK9 Inhibitors. Manolis, Antonis S.; Manolis, Theodora A.; Melita, Helen // Hospital Chronicles;2014, Vol. 9 Issue 1, p3 

    Proprotein convertase subtilisin/kexin type 9 (PCSK9) was recently discovered as the third gene involved in autosomal dominant familial hypercholesterolemia. The encoded PCSK9 protein binds and induces degradation of the low-density lipoprotein (LDL) receptor and thereby modulates the plasma...

  • The Incidence of Japanese Encephalitis in Taiwan—A Population-Based Study. Hsu, Li-Ching; Chen, Yu-Ju; Hsu, Feng-Kuang; Huang, Jyh-Hsiung; Chang, Chi-Ming; Chou, Pesus; Lin, I-Feng; Chang, Feng-Yee // PLoS Neglected Tropical Diseases;Jul2014, Vol. 8 Issue 7, p1 

    Background: A mass Japanese encephalitis (JE) vaccination program targeting children was launched in Taiwan in 1968, and the number of pediatric JE cases substantially decreased thereafter. The aim of this study was to elucidate the long-term trend of JE incidence, and to investigate the...

  • In vivo bypass of hemophilia A coagulation defect by Factor XIIa implant. Ton-That, Tung T.; Doron, David; Pollard, Bette S.; Bacher, John; Pollard, Harvey B. // Nature Biotechnology;Mar2000, Vol. 18 Issue 3, p289 

    Hemophilia A and B coagulation defects, which are caused by deficiencies of Factor VIII and Factor IX, respectively, can be bypassed by administration of recombinant Factor VIIa. However, the short half-life of recombinant Factor VIIa in vivo negates its routine clinical use. We report here an...

  • Hemophilia with Factor VIII Inhibitor. Stein, Richard S.; Colman, Robert W. // Annals of Internal Medicine;Jul73, Vol. 79 Issue 1, p84 

    Presents a study which described a case on the elimination of factor VIII inhibitors after a combined treatment with factor VIII of hemophilia. Materials and methods; Results; Discussion.

  • Suppression of Factor IX Antibody in Hemophilia B by Factor IX and Cyclophosphamide. Nilsson, I.M.; Hedner, U.; Bjorlin, G. // Annals of Internal Medicine;Jan73, Vol. 78 Issue 1, p91 

    Focuses on a study which described two patients with severe hemophilia B complicated by inhibitors of factor IX. Plasma inhibition of normal plasma recaldification time; Measurement of factor IX inhibitor; Treatment.

  • Consensus recommendations for the diagnosis and treatment of acquired hemophilia A. Collins, Peter; Baudo, Francesco; Huth-Kühne, Angela; Ingerslev, Jørgen; Kessler, Craig M.; Castellano, Maria E. Mingot; Shima, Midori; St-Louis, Jean; Lévesque, Hervé // BMC Research Notes;2010, Vol. 3, p161 

    Background: Acquired hemophilia A (AHA) is a rare bleeding disorder caused by an autoantibody to coagulation factor (F) VIII. It is characterized by soft tissue bleeding in patients without a personal or family history of bleeding. Bleeding is variable, ranging from acute, life-threatening...

  • Hemophilia.  // Diseases & Disorders: A Nursing Therapeutics Manual, 2nd edition;2002, p421 

    Provides information on hemophilia, a group of congenital coagulation disorders characterized by a deficiency of specific clotting factors. Types of hemophilia; Medical conditions associated with the disease; Causes of the disease; Clinical diagnosis and management of the disease.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics